HDAC-Inhibitor Linker Antibody–Drug Conjugates for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) face challenges in targeting epigenetic regulatory enzymes for solid tumors, with limited therapeutic efficacy and stability, necessitating the development of novel linker-based ADCs to enhance anti-tumor activity and stability.
Innovation Solution
A linker structure represented by general formula (I) and a conjugate structure represented by formula (II) are developed, incorporating histone deacetylase inhibitors, which are linked to antibodies through specific amino acid residues and peptides, enhancing stability and anti-tumor efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapy is used, then cytotoxic drugs can kill tumor cells, but targeting property is poor and toxic side effects are strong
Solution Approach 1:
The chemotherapy system is segmented into three distinct components: a targeting antibody, a linker, and a cytotoxic payload. The antibody specifically binds to tumor cell surface antigens, while the cytotoxic drug is conjugated via a linker, enabling selective delivery to tumor cells and reducing systemic toxicity.
Solution Approach 2:
The linker serves as an intermediary component that connects the antibody and cytotoxic payload. It enables controlled drug release through specific cleavage mechanisms (such as protease-sensitive or pH-sensitive linkers), ensuring the cytotoxic agent is released only at the target site and not during circulation.
2Reliability
If epigenetic drugs are used as monotherapy, then clinical efficacy is achieved in hematological tumors, but therapeutic efficacy in solid tumors is limited
Solution Approach 1:
The patent merges epigenetic modulation (via HDAC inhibitor payload) with targeted delivery (via antibody-conjugate system). This combination approach allows the ADC to deliver high concentrations of the epigenetic drug specifically to solid tumors, overcoming the limitations of monotherapy and enabling efficacy in previously resistant indications.
3Reliability
If ADCs are developed to target solid tumors, then anti-tumor activity is enhanced, but plasma stability is reduced
Solution Approach 1:
The patent optimizes linker parameters including bond strength, hydrophilicity, and molecular weight to achieve the desired balance. The linker is designed with specific chemical properties (such as PEGylation or specific amino acid sequences) that enhance plasma stability by reducing premature cleavage and aggregation, while maintaining the ability to release the payload at the target site.
Data Source
Figure 1-1~1-2
Figure 1-3~1-4
Figure 1-5~1-6
AI summary
Provided is a linker-containing antibody drug conjugate. Also involved are a pharmaceutical composition comprising the antibody conjugate, a use of a linker, and a use of the antibody conjugate in the preparation for a drug for preventing and/or treating diseases.